AroCell presenterar resultat från U-CAN TK1 lymfomstudien samt från en studie där TK 210™ ELISA jämförs med andra metoder I samband med ISOBMs kongress (International Society of Oncology Biomarkers) i Hamburg, presenterar idag AroCell’s forskningschef, Staffan Eriksson, nya preliminära kliniska resultat från U-CAN TK1...

AroCell presents results from the U-CAN TK1 lymphoma study and from a comparison study between TK 210™ ELISA and other assays AroCell’s Chief Scientific Officer, Professor Staffan Eriksson, presents today new preliminary results from the U-CAN TK1 lymphoma study at the International Society of Oncology Biomarkers (ISOBM) in...

New Publication from AroCell AB Demonstrating the Value of Thymidine Kinase 1 as a Tumor Biomarker A new review article has been published, Thymidine Kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker, that analyses and summarizes recent publications...